{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-23-000126","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.862839+00:00","generated_at":"2026-06-11T22:36:42.417582+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Praxis posts Q2 net loss $34.3M, plans ulixacaltamide Phase 3 after FDA meeting","bullets":["Q2 net loss $34.3M, cash $124.3M; cash runway into Q1 2025 from June offering net $63.4M.","Ulixacaltamide: FDA EOP2 meeting confirms Phase 3 plan; two studies starting Q4 2023, mADL11 primary endpoint, 60 mg, 12 weeks.","PRAX-628 Phase 1 EEG showed pharmacodynamic activity at all doses; Phase 2 PPR study topline H2 2023; focal epilepsy Phase 2 H1 2024.","Net loss $34.3M in Q2 2023 vs $60.2M in Q2 2022; R&D expenses $25.6M down from $43.6M.","R&D Portfolio Day on Oct 2, 2023 to detail Phase 3 program for ulixacaltamide and additional Essential1 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-23-000126","json":"https://secwatch.observer/filing/0001689548-23-000126.json","markdown":"https://secwatch.observer/filing/0001689548-23-000126.md","text":"https://secwatch.observer/filing/0001689548-23-000126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/0001689548-23-000126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/prax-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:36:42.417582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3397f3cd3496fddd3153208e8f0b87682834d006","claim":"Praxis Precision Medicines, Inc. reported financial results for second quarter 2023.","evidence_excerpt":"Praxis Precision Medicines, Inc. (the \"Company\") announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000126/0001689548-23-000126-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}